Collaborations & licenses
Gaining momentum
Since our inception, strategic business development has been a core pillar of our strategy to advance a broad, diverse and well-balanced portfolio of first- and best-in-class medicines and bring them to patients globally.
We actively seek collaboration or licensing opportunities that complement our existing portfolio and research focus. If you or your company are interested in partnering opportunities, please contact us.
Collaborations
In June 2018, we entered into a collaboration with CStone Pharmaceuticals to develop and commercialize clinical-stage therapeutic candidates, including avapritinib and pralsetinib, in Greater China (Mainland China, Hong Kong, Macau and Taiwan).
In November 2021, we entered into a collaboration with Zai Lab to develop and commercialize BLU-945 and BLU-701, including back-up candidates, for the treatment of EGFR-driven non-small cell lung cancer in Greater China (Mainland China, Hong Kong, Macau and Taiwan). Under the collaboration, Zai Lab has rights to the licensed therapeutic candidates in Greater China, and Blueprint Medicines retains all rights in the rest of the world.
In December 2023, we entered into an amended agreement with VantAI to design and advance novel targeted protein degrader therapies. Under the agreement, which builds on a collaboration initiated in February 2022, we will jointly research and advance up to three novel protein degrader target programs into development candidates, and at our discretion, we have the option to expand the collaboration to one additional target program.
Licenses
In October 2019, we entered into an exclusive, worldwide license agreement with Clementia Pharmaceuticals, a subsidiary of Ipsen, for fidrisertib (formerly known as BLU-782 or IPN60130), an investigational ALK2 inhibitor being developed for the treatment of fibrodysplasia ossificans progressiva (FOP).
In August 2022, we entered into an exclusive, worldwide license agreement with IDRx, Inc. to develop a KIT exon 13 inhibitor for the treatment of gastrointestinal stromal tumor (GIST).
In February 2024, we entered into an agreement granting Rigel Pharmaceuticals the U.S. rights to GAVRETO® (pralsetinib).